2376 related articles for article (PubMed ID: 34990339)
1. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
[TBL] [Abstract][Full Text] [Related]
2. Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development.
Claxton K; Palmer S; Longworth L; Bojke L; Griffin S; McKenna C; Soares M; Spackman E; Youn J
Health Technol Assess; 2012; 16(46):1-323. PubMed ID: 23177626
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of therapeutics for COVID-19 patients: a rapid review and economic analysis.
Metry A; Pandor A; Ren S; Shippam A; Clowes M; Dark P; McMullan R; Stevenson M
Health Technol Assess; 2023 Aug; 27(14):1-92. PubMed ID: 37840452
[TBL] [Abstract][Full Text] [Related]
4. Developing a reference protocol for structured expert elicitation in health-care decision-making: a mixed-methods study.
Bojke L; Soares M; Claxton K; Colson A; Fox A; Jackson C; Jankovic D; Morton A; Sharples L; Taylor A
Health Technol Assess; 2021 Jun; 25(37):1-124. PubMed ID: 34105510
[TBL] [Abstract][Full Text] [Related]
5. Economic modelling of diagnostic and treatment pathways in National Institute for Health and Care Excellence clinical guidelines: the Modelling Algorithm Pathways in Guidelines (MAPGuide) project.
Lord J; Willis S; Eatock J; Tappenden P; Trapero-Bertran M; Miners A; Crossan C; Westby M; Anagnostou A; Taylor S; Mavranezouli I; Wonderling D; Alderson P; Ruiz F
Health Technol Assess; 2013 Dec; 17(58):v-vi, 1-192. PubMed ID: 24325843
[TBL] [Abstract][Full Text] [Related]
6. The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal.
Hettle R; Corbett M; Hinde S; Hodgson R; Jones-Diette J; Woolacott N; Palmer S
Health Technol Assess; 2017 Feb; 21(7):1-204. PubMed ID: 28244858
[TBL] [Abstract][Full Text] [Related]
7. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers for assessing acute kidney injury for people who are being considered for admission to critical care: a systematic review and cost-effectiveness analysis.
Brazzelli M; Aucott L; Aceves-Martins M; Robertson C; Jacobsen E; Imamura M; Poobalan A; Manson P; Scotland G; Kaye C; Sawhney S; Boyers D
Health Technol Assess; 2022 Jan; 26(7):1-286. PubMed ID: 35115079
[TBL] [Abstract][Full Text] [Related]
9. Interventions to reduce the risk of surgically transmitted Creutzfeldt-Jakob disease: a cost-effective modelling review.
Stevenson M; Uttley L; Oakley JE; Carroll C; Chick SE; Wong R
Health Technol Assess; 2020 Feb; 24(11):1-150. PubMed ID: 32122460
[TBL] [Abstract][Full Text] [Related]
10. EarlyCDT Lung blood test for risk classification of solid pulmonary nodules: systematic review and economic evaluation.
Duarte A; Corbett M; Melton H; Harden M; Palmer S; Soares M; Simmonds M
Health Technol Assess; 2022 Dec; 26(49):1-184. PubMed ID: 36534989
[TBL] [Abstract][Full Text] [Related]
11. Tumour necrosis factor-α inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation.
Corbett M; Soares M; Jhuti G; Rice S; Spackman E; Sideris E; Moe-Byrne T; Fox D; Marzo-Ortega H; Kay L; Woolacott N; Palmer S
Health Technol Assess; 2016 Feb; 20(9):1-334, v-vi. PubMed ID: 26847392
[TBL] [Abstract][Full Text] [Related]
12. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
[TBL] [Abstract][Full Text] [Related]
13. What is the value of routinely testing full blood count, electrolytes and urea, and pulmonary function tests before elective surgery in patients with no apparent clinical indication and in subgroups of patients with common comorbidities: a systematic review of the clinical and cost-effective literature.
Czoski-Murray C; Lloyd Jones M; McCabe C; Claxton K; Oluboyede Y; Roberts J; Nicholl JP; Rees A; Reilly CS; Young D; Fleming T
Health Technol Assess; 2012 Dec; 16(50):i-xvi, 1-159. PubMed ID: 23302507
[TBL] [Abstract][Full Text] [Related]
14. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic accuracy and clinical impact of MRI-based technologies for patients with non-alcoholic fatty liver disease: systematic review and economic evaluation.
Bresnahan R; Duarte R; Mahon J; Beale S; Chaplin M; Bhattacharyya D; Houten R; Edwards K; Nevitt S; Maden M; Boland A
Health Technol Assess; 2023 Jul; 27(10):1-115. PubMed ID: 37839810
[TBL] [Abstract][Full Text] [Related]
16. The Effectiveness of Integrated Care Pathways for Adults and Children in Health Care Settings: A Systematic Review.
Allen D; Gillen E; Rixson L
JBI Libr Syst Rev; 2009; 7(3):80-129. PubMed ID: 27820426
[TBL] [Abstract][Full Text] [Related]
17. Oral nutritional interventions in frail older people who are malnourished or at risk of malnutrition: a systematic review.
Thomson K; Rice S; Arisa O; Johnson E; Tanner L; Marshall C; Sotire T; Richmond C; O'Keefe H; Mohammed W; Gosney M; Raffle A; Hanratty B; McEvoy CT; Craig D; Ramsay SE
Health Technol Assess; 2022 Dec; 26(51):1-112. PubMed ID: 36541454
[TBL] [Abstract][Full Text] [Related]
18. Including adverse drug events in economic evaluations of anti-tumour necrosis factor-α drugs for adult rheumatoid arthritis: a systematic review of economic decision analytic models.
Heather EM; Payne K; Harrison M; Symmons DP
Pharmacoeconomics; 2014 Feb; 32(2):109-34. PubMed ID: 24338344
[TBL] [Abstract][Full Text] [Related]
19. Models and applications for measuring the impact of health research: update of a systematic review for the Health Technology Assessment programme.
Raftery J; Hanney S; Greenhalgh T; Glover M; Blatch-Jones A
Health Technol Assess; 2016 Oct; 20(76):1-254. PubMed ID: 27767013
[TBL] [Abstract][Full Text] [Related]
20. Optimal surveillance strategies for patients with stage 1 cutaneous melanoma post primary tumour excision: three systematic reviews and an economic model.
Vale L; Kunonga P; Coughlan D; Kontogiannis V; Astin M; Beyer F; Richmond C; Wilson D; Bajwa D; Javanbakht M; Bryant A; Akor W; Craig D; Lovat P; Labus M; Nasr B; Cunliffe T; Hinde H; Shawgi M; Saleh D; Royle P; Steward P; Lucas R; Ellis R
Health Technol Assess; 2021 Nov; 25(64):1-178. PubMed ID: 34792018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
